cbdMD (YCBD) Depreciation & Amortization (CF) (2016 - 2026)
cbdMD (YCBD) posted Depreciation & Amortization (CF) of $54160.0 for Q4 2025, down 23.49% sequentially from $70788.0 in Q3 2025, and down 49.26% YoY from $106740.0 in Q4 2024.
cbdMD (YCBD) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
cbdMD has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $54160.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 49.26% year-over-year to $54160.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $308483.0 (down 31.17% YoY) and the FY2025 annual result came in at $361063.0, down 20.18% from the prior year.
- Depreciation & Amortization (CF) slipped to $54160.0 in Q4 2025 per YCBD's latest filing, from $70788.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $340701.0 in Q4 2021 and troughed at $54160.0 in Q4 2025.
- A 5-year average of $158186.4 and a median of $114912.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2021 and 2022: Depreciation & Amortization (CF) jumped 46.44% in 2021, then tumbled 70.62% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $340701.0 in 2021, then sank by 70.62% to $100112.0 in 2022, then increased by 10.74% to $110864.0 in 2023, then fell by 3.72% to $106740.0 in 2024, then tumbled by 49.26% to $54160.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $54160.0, $70788.0, and $88906.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,344.00 |
| Jun 30, 2026 | 44,344.00 |
| Dec 31, 2025 | 54,160.00 |
| Dec 31, 2025 | 54,160.00 |
| Sep 30, 2025 | 70,788.00 |
| Sep 30, 2025 | 70,788.00 |
| Jun 30, 2025 | 88,906.00 |
| Jun 30, 2025 | 88,906.00 |
| Mar 31, 2025 | 94,629.00 |
| Mar 31, 2025 | 94,629.00 |
| Dec 31, 2024 | 106,740.00 |
| Dec 31, 2024 | 106,740.00 |
| Sep 30, 2024 | 108,799.00 |
| Sep 30, 2024 | 108,799.00 |
| Jun 30, 2024 | 114,912.00 |
| Jun 30, 2024 | 114,912.00 |
| Mar 31, 2024 | 117,751.00 |
| Mar 31, 2024 | 117,751.00 |
| Dec 31, 2023 | 110,864.00 |
| Dec 31, 2023 | 110,864.00 |